Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.38 |
| ▸ | GABRR1 | P24046 | 2/20 | 0.36 |
| ▸ | OPRD1 | P41143 | 2/20 | 0.36 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8310688 | 0.86 | SIGMAR1 (0.41) | SIGMAR1OPRD1SLC6A4 | |
| SCHEMBL8387444 | 0.86 | GSR (0.42) | SIGMAR1 | |
| SCHEMBL2764645 | 0.85 | SIGMAR1 (0.38) | SIGMAR1OPRD1SLC6A4 | |
| SCHEMBL7842583 | 0.84 | SIGMAR1 (0.38) | SIGMAR1OPRD1 | |
| SCHEMBL28478812 | 0.83 | SIGMAR1 (0.39) | SIGMAR1OPRD1SLC6A4 | |
| SCHEMBL29004649 | 0.81 | SIGMAR1 (0.48) | SIGMAR1SLC6A4 | |
| SCHEMBL30598638 | 0.81 | SIGMAR1 (0.38) | SIGMAR1OPRD1SLC6A4 | |
| SCHEMBL28335967 | 0.81 | CYP1A2 (0.41) | SIGMAR1OPRD1 | |
| SCHEMBL25415951 | 0.80 | CYP1A2 (0.39) | SIGMAR1OPRD1 | |
| SCHEMBL7883626 | 0.80 | CYP1A2 (0.39) | SIGMAR1OPRD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1844070-B1 | PEPTIDES WITH NEUROPEPTIDE-2 RECEPTOR (Y2R) AGONIST ACTIVITY | HOFFMANN LA ROCHE (CH) | 2011-03-02 | — | — | EP | claimed |
| US-7410949-B2 | Genetically engineered truncated analogs of significantly lower-molecular-weight and having equal or better potency, pharmacokinetic properties and pharmacological properties as existing Y2R agonists; also pegylated analogs; treating obesity; dietetics; metabolic disorders | HOFFMANN-LA ROCHE INC. (US) | 2008-08-12 | — | — | US | claimed |
| US-20060160742-A1 | Neuropeptide-2 receptor (Y-2R) agonists and uses thereof | DANHO WALEED | 2006-07-20 | — | — | US | claimed |
| US-20250319214-A1 | A NOVEL KIT FOR RADIOPHARMACEUTICAL PREPARATION OF A RADIOMETAL LABELED CHELATE-FUNCTIONALIZED TARGETING CONJUGATE | Life Molecular Imaging Ltd. (GB) | 2025-10-16 | — | — | US | disclosed |
| EP-2252628-B1 | BOMBESIN ANALOG PEPTIDE ANTAGONIST CONJUGATES | UNIVERSITÄTSSPITAL BASEL (CH) | 2016-12-28 | — | — | EP | disclosed |
| US-20150265733-A1 | BOMBESIN ANALOG PEPTIDE ANTAGONIST CONJUGATES | Universität Bern (CH) | 2015-09-24 | — | — | US | disclosed |
| US-9035023-B2 | Bombesin analog peptide antagonist conjugates | Piramal Imaging, SA (CH) | 2015-05-19 | — | — | US | disclosed |
| US-20110097266-A1 | Bombesin Analog Peptide Antagonist Conjugates | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2011-04-28 | — | — | US | disclosed |
| EP-1844070-B1 | PEPTIDES WITH NEUROPEPTIDE-2 RECEPTOR (Y2R) AGONIST ACTIVITY | HOFFMANN LA ROCHE (CH) | 2011-03-02 | — | — | EP | disclosed |
| EP-2100900-A1 | Bombesin analog peptide antagonist conjugates | Universitätsspital Basel (CH) | 2009-09-16 | — | — | EP | disclosed |
| US-7410949-B2 | Genetically engineered truncated analogs of significantly lower-molecular-weight and having equal or better potency, pharmacokinetic properties and pharmacological properties as existing Y2R agonists; also pegylated analogs; treating obesity; dietetics; metabolic disorders | HOFFMANN-LA ROCHE INC. (US) | 2008-08-12 | — | — | US | disclosed |
| US-20060160742-A1 | Neuropeptide-2 receptor (Y-2R) agonists and uses thereof | DANHO WALEED | 2006-07-20 | — | — | US | disclosed |
| US-6844318-B2 | Peptidase-cleavable, targeted antineoplastic drugs and their therapeutic use | BRISTOL MYERS SQUIBB PHARMA COMPANY (US) | 2005-01-18 | — | — | US | disclosed |
| US-20020103133-A1 | Peptidase-cleavable, targeted antineoplastic drugs and their therapeutic use | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2002-08-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060160742-A1 | Neuropeptide-2 receptor (Y-2R) agonists and uses thereof | NPY2R, NPY1R, NPY4R | SIGMAR1 215/4885GABRR1 331/4885OPRD1 120/4885 |
| US-20110097266-A1 | Bombesin Analog Peptide Antagonist Conjugates | BRS3, VIP, GRPR | SIGMAR1 1327/4885GABRR1 672/4885OPRD1 949/4885 |
| US-20150265733-A1 | BOMBESIN ANALOG PEPTIDE ANTAGONIST CONJUGATES | BRS3, VIP, GRPR | SIGMAR1 1153/4885GABRR1 569/4885OPRD1 699/4885 |
| US-20020103133-A1 | Peptidase-cleavable, targeted antineoplastic drugs and their therapeutic use | DNPEP, TMPRSS15, ENPEP | SIGMAR1 4271/4885GABRR1 3396/4885OPRD1 4410/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.